cytarabine

Type: Keyphrase
Name: cytarabine
First reported 6 hours ago - Updated 6 hours ago - 1 reports

ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia

LYON, France--(BUSINESS WIRE)--Regulatory News:ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications ... [Published BioSpace - 6 hours ago]
First reported Aug 23 2014 - Updated Aug 24 2014 - 1 reports

With Cyclacel, The Waiting Is The Hardest Part

Summary Cyclacel shares have weakened as investors have avoided riskier biotechs, and perhaps due to some worries about potential competitive drugs sponsored by larger companies in pharma/biotech. A decision to launch a Phase IIb study in r-MDS was ... [Published Seeking Alpha - Aug 23 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 2 reports

Celator Pharma Says First Patient Enrolled In Phase 2 CPX-351 Study

Celator Pharma says first patient enrolled in Phase 2 CPX-351 studyCelator Pharmaceuticals, Inc. (CPXX: Quote), a pharmaceutical company developing new and more effective therapies to treat cancer, Tuesday said the first patient has been enrolled in a ... [Published RTTNews.com - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Combination therapy for the treatment of cancer

Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a ... [Published Free Patents Online - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2014.SECOND ... [Published BioSpace - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

New Nanoparticles Findings from University of Texas Described [Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl...

New Nanoparticles Findings from University of Texas Described [Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 ...]By a News Reporter-Staff ... [Published HispanicBusiness.com - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q2 2014 Results - Earnings Call Transcript

OperatorGood afternoon and welcome to Cyclacel Pharmaceuticals’ Second Quarter 2014 Earnings Conference Call and Webcast. Today’s call is being recorded. At this time, all participants have been placed in a listen-only mode and the floor will be opened ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Celator(R) Pharmaceuticals Announces Business Update and Second Quarter 2014 Financial Results

EWING, N.J., Aug. 7, 2014 (GLOBE NEWSWIRE) -- . (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the second quarter ended June 30, 2014."In ... [Published EMoneyDaily - Aug 07 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 2 reports

Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q2 2014 Results - Earnings Call Transcript

OperatorGood day, ladies and gentlemen, and welcome to the Second Quarter 2014 Sunesis Pharmaceuticals Inc. Earnings Conference Call. My name is Philip, and I will be your operator for today. [Operator Instructions] As a reminder that this conference ... [Published Seeking Alpha - Aug 06 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Celator(R) Pharmaceuticals to Report Second Quarter 2014 Financial Results on August 7, 2014

(GLOBE NEWSWIRE) -- ., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 7, 2014 at 4:30 p.m. ET to report ... [Published Pettinga Financial Advisors - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Synta Updates on Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Trial [Professional Services Close - Up]

Synta Pharmaceuticals Corp. reported the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial.AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ... [Published Pharmacy Choice - Jul 30 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Celator: A Unique Drug Ratio Technology Company For Cancer

By Tony Schwartz, PhD :Company OverviewRelated Biotechnology, Pharmaceutical and Healthcare NewsCelator Pharmaceuticals (NASDAQ: CPXX ) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various ... [Published BioPortfolio - Jul 23 2014]

Quotes

...new treatment option for patients with acute hematologic malignancies," said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals. "The FDA requires clinical pharmacology studies for new drugs in development, so we are pleased to have this Phase 2 study underway to support our plans for a NDA submission. We expect to report top-line results from this study in the second half of 2015. "
"The gas-filled microcapsules are useful as contrast agents in medical imaging, such as diagnostic ultrasound. Ultrasound contrast compositions typically comprise the hollow or porous polymer microcapsules, filled with a gas, and dispersed is an aqueous liquid which serves as a carrier for the contrast agent. Aqueous liquids that can be used include, but are not limited to, isotonic saline and phosphate-buffered saline. The contrast agent composition is then injected into the bloodstream and used for ultrasound visualization of specific blood vessels or body organs."

More Content

All (67) | News (56) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
ERYtech Pharma Announces Second Positive DSMB R... [Published BioSpace - 6 hours ago]
ERYTECH Announces Second Positive DSMB Review o... [Published Crawford Financial Planning - 9 hours ago]
With Cyclacel, The Waiting Is The Hardest Part [Published Seeking Alpha - Aug 23 2014]
Celator Pharma Says First Patient Enrolled In P... [Published RTTNews.com - Aug 19 2014]
Celator(R) Pharmaceuticals Initiates Pharmacoki... [Published GlobeNewswire: Acquisitions News - Aug 19 2014]
Celator(R) Pharmaceuticals Initiates Pharmacoki... [Published Town Hall - Aug 19 2014]
Combination therapy for the treatment of cancer [Published Free Patents Online - Aug 19 2014]
Bio-Path Holdings Reports Second Quarter 2014 O... [Published BioSpace - Aug 18 2014]
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
"Precursors to Echogenic Polymer Microcapsules ... [Published HispanicBusiness.com - Aug 14 2014]
New Nanoparticles Findings from University of T... [Published HispanicBusiness.com - Aug 14 2014]
Ambit Biosciences' (AMBI) CEO Mike Martino on Q... [Published Seeking Alpha - Aug 13 2014]
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Romb... [Published Seeking Alpha - Aug 13 2014]
Special Report: Finally beyond the hype? [Published Drug Discovery News - Aug 12 2014]
Synta Reports Second Quarter Financial Results ... [Published FiercePharma - Aug 11 2014]
Karyopharm Therapeutics' (KPTI) CEO Michael Kau... [Published Seeking Alpha - Aug 08 2014]
Celator Pharmaceuticals' (CPXX) CEO Scott Jacks... [Published Seeking Alpha - Aug 08 2014]
Celator Pharmaceuticals Given Outperform Rating... [Published American Banking News - Aug 08 2014]
Celator(R) Pharmaceuticals Announces Business U... [Published EMoneyDaily - Aug 07 2014]
Karyopharm Therapeutics Reports Second Quarter ... [Published Virtual Strategy Magazine - Aug 07 2014]
Synta Pharmaceuticals (SNTA) Q2 2014 Results - ... [Published Seeking Alpha - Aug 06 2014]
Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swis... [Published Seeking Alpha - Aug 06 2014]
Sunesis Pharmaceuticals Reports Second Quarter ... [Published CBS Detroit - Aug 05 2014]
Interim results for the six months ended 30 Jun... [Published MarketWired - Aug 05 2014]
CTI BioPharma's (CTIC) CEO Jim Bianco on Q2 201... [Published Seeking Alpha - Aug 05 2014]
Celator(R) Pharmaceuticals to Report Second Qua... [Published Pettinga Financial Advisors - Jul 31 2014]
Synta Updates on Advancement of Ganetespib into... [Published Pharmacy Choice - Jul 30 2014]
Baylor Sammons Cancer Center Joins as Clinical ... [Published Wall Street Select - Jul 30 2014]
Findings from University Medical Center Provide... [Published Pharmacy Choice - Jul 28 2014]
Mylotarg Boosts Survival in Acute Myeloid Leukemia [Published American Journal of Public Health - Jul 24 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ...
Boehringer Ingelheim's volasertib Phase II data... [Published PR Newswire: Health - Jul 08 2014]
RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published ...
CYTARABINE Injection, Powder, Lyophilized, For ... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 12, 2014 EST ...
CYTARABINE Injection, Powder, Lyophilized, For ... [Published DailyMed Drug Label Updates for the last seven ... - Jun 12 2014]
Updated Date: Jun 12, 2014 EST ...
CTI Announces United Kingdom National Cancer Re... [Published PR Newswire: Health - Jun 12 2014]
SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients ...
1 2

Press Releases

sort by: Date | Relevance
Celator(R) Pharmaceuticals Initiates Pharmacoki... [Published GlobeNewswire: Acquisitions News - Aug 19 2014]
Celator(R) Pharmaceuticals Announces Data and S... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Celator(R) Pharmaceuticals Reaches 75% Enrollme... [Published GlobeNewswire: Acquisitions News - Jun 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.